Depression has traditionally been understood as a disorder linked to brain chemistry, psychological stress, and environmental influences. However, a growing body of research suggests that inflammation may also play an important role in at least a subset of patients. A newly published clinical trial in JAMA Psychiatry offers early evidence that targeting a specific inflammatory pathway could represent a future therapeutic direction for individuals with difficult-to-treat depression.
The Insight trial was a UK-based proof-of-concept, randomized, double-blind, placebo-controlled study (2018–2022) testing whether blocking interleukin-6 (IL-6), a key inflammatory molecule, could improve symptoms in adults with persistent depression. IL-6 has been linked to mood regulation in genetic, experimental, and observational studies, but clinical testing in depression has been scarce. The trial enrolled adults with moderate-to-severe depression who had not responded to antidepressants. To target inflammation-related disease activity, participants were required to show persistent elevation of high-sensitivity C-reactive protein (hs-CRP) and clinically significant somatic symptoms of depression.
Participants received either a single intravenous infusion of tocilizumab, an IL-6 receptor antagonist already used in inflammatory conditions or placebo saline. Clinical assessments were performed at baseline and during follow-up visits at 7, 14, and 28 days after treatment. Outcomes included somatic depressive symptoms, overall depression severity, fatigue, anxiety, quality of life, cognition, and symptom-level changes. Thirty participants were randomized, and 29 completed treatment and follow-up. Although the study was intentionally small and not powered to establish definitive efficacy, several encouraging patterns emerged. The primary endpoint improvement in somatic symptoms at day 14, did not reach statistical significance. Nevertheless, individuals receiving tocilizumab showed a gradual pattern of improvement over time across several clinically relevant outcomes compared with placebo.
The strongest signals appeared in overall depression severity, fatigue, anxiety, and quality-of-life measures. By the final follow-up visit, remission occurred more frequently among participants treated with tocilizumab than among those receiving placebo. Response rates also favoured the active treatment group. Researchers emphasized that these findings should be interpreted cautiously because confidence intervals remained wide and included the possibility of no treatment effect. One of the most notable observations involved biomarkers. Baseline hs-CRP levels appeared to predict treatment response more consistently than IL-6 concentrations themselves. Participants with higher inflammatory burden tended to experience greater symptom improvement following IL-6 receptor blockade. This finding aligns with earlier research suggesting that inflammatory markers may help identify patients who are more likely to benefit from immunomodulatory strategies.
The current study builds on earlier work by Raison et al., which demonstrated that patients with treatment-resistant depression and elevated inflammatory biomarkers derived greater benefit from immune-targeted cytokine blockade. The IL-6 as a treatment target for depression study extends this approach by specifically targeting the IL-6 signaling pathway in individuals with depression and low-grade systemic inflammation. Unlike earlier studies focused mainly on overall antidepressant response, this trial used biomarker-guided patient selection and assessed depressive symptom domains, remission rates, and quality-of-life outcomes. By integrating inflammatory profiling with targeted immunomodulation, the study moves toward a precision psychiatry framework that aligns treatment with underlying biological mechanisms rather than relying solely on symptom-based classification.
Symptom-level analyses suggested improvements in fatigue, energy, concentration, appetite, pessimism, agitation, and feelings of worthlessness. In contrast, the intervention did not demonstrate meaningful effects on cognition or anhedonia during the short study period. Importantly, treatment was well tolerated, with no serious adverse events reported and no withdrawals attributed to safety concerns. While these results do not support immediate clinical adoption, they strengthen the emerging concept that depression may encompass biologically distinct subtypes. For patients whose symptoms are linked to chronic low-grade inflammation, targeted immune therapies may eventually complement existing antidepressant approaches. Larger and longer-duration trials will now be needed to determine whether IL-6 inhibition can deliver sustained and clinically meaningful benefit in routine practice.
References
- Foley ÉM, Turner N, Margelyte R, Jones HJ, Kaser M, Lewis G, et al. Interleukin 6 as a Treatment Target for Depression: A Proof-of-Concept Randomized Clinical Trial. JAMA psychiatry. 2026 May 20.
- Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA psychiatry. 2013 Jan 1;70(1):31-41.